

Heidelberg Pharma AG

WKN: A11QVV **ISIN:** DE000A11QVV0 **Land:** Deutschland

Nachricht vom 06.02.2018 | 12:09

Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Heidelberg Pharma AG

06.02.2018 / 12:09

Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany

2. Reason for notification

<input type="checkbox"/>	Acquisition/disposal of shares with voting rights
<input type="checkbox"/>	Acquisition/disposal of instruments
<input checked="" type="checkbox"/>	Change of breakdown of voting rights
<input type="checkbox"/>	Other reason:

3. Details of person subject to the notification obligation

Name:	City and country of registered office:
UCB SA	Brussels Belgium

4. Names of shareholder(s)

holding directly 3% or more voting rights, if different from 3.

UCB Biopharma SPRL

5. Date on which threshold was crossed or reached:

31 Jan 2018

6. Total positions

	% of voting rights attached to shares (total of 7.a.)	% of voting rights through instruments (total of 7.b.1 + 7.b.2)	total of both in % (7.a. + 7.b.)	total number of voting rights of issuer
Resulting situation	4.03 %	0.0 %	4.03 %	28095419
Previous notification	8.75 %	0.0 %	8.75 %	/

7. Notified details of the resulting situation

a. Voting rights attached to shares (Sec.s 33, 34 WpHG)

ISIN	absolute		in %	
	direct (Sec. 33 WpHG)	indirect (Sec. 34 WpHG)	direct (Sec. 33 WpHG)	indirect (Sec. 34 WpHG)
DE000A11QVV0	0	1131186	0 %	4.03 %
Total	1131186		4.03 %	

b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Voting rights absolute	Voting rights in %
				%
		Total		%

b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG

Type of instrument	Expiration or maturity date	Exercise or conversion period	Cash or physical settlement	Voting rights absolute	Voting rights in %
					%
			Total		%

8. Information in relation to the person subject to the notification obligation

<input type="checkbox"/>	Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
<input checked="" type="checkbox"/>	Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name	% of voting rights (if at least held 3% or more)	% of voting rights through instruments (if at least held 5% or more)	Total of both (if at least held 5% or more)
UCB SA	- %	- %	- %
UCB Pharma SA	- %	- %	- %
UCB Biopharma SPRL	4.03 %	- %	- %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG

Date of general meeting:	
Holding position after general meeting:	% (equals voting rights)

10. Other explanatory remarks:

--

06.02.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Internet: www.heidelberg-pharma.com

End of News DGAP News Service